U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07184905) titled 'Oral Bifidobacterium Longum for Skin Barrier Dysfunction in Obesity' on Aug. 06.
Brief Summary: This clinical trial aims to evaluate the safety and efficacy of oral Bifidobacterium longum supplementation for treating obesity-induced skin barrier impairment in individuals aged 18-40 with BMI >=30, compared to healthy controls. The study focuses on the following questions:
Can oral Bifidobacterium supplementation reduce skin barrier damage (measured by transepidermal water loss/TEWL) in obese participants? Does modulation of gut microbiota with Bifidobacterium longum impact skin barrier function and systemic inflammation?
Researche...